CordIn is under clinical development by Gamida Cell and currently in Phase II for Aplastic Anemia. According to GlobalData, Phase II drugs for Aplastic Anemia have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CordIn’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CordIn overview
CordIn is under development for the treatment of hemoglobinopathies including aplastic anemia and hypo-plastic myelodysplastic syndrome. It is administered as an intravenous infusion. The therapeutic candidate is CD133+ cells derived from allogenic umbilical cord blood cells. The drug candidate is developed based on NAM platform technology. It was under development for sickle cell disease and beta thalassaemia.
Gamida Cell overview
Gamida Cell (Gamida) is a healthcare company that develops allogeneic cell therapy products and candidates. Its proprietary nicotinamide (NAM) technology enhances and expands cells, creating allogeneic cell therapy products and candidates for patients with hematologic malignancies. The company’s pipeline products include omidubicel which treats hematologic malignancies and severe aplastic anemia and GDA-201 which is a natural killer (NK) cell therapy candidate for the treatment of non-hodgkin lymphoma. Its brand include Omisirge. The company collaborates with advocacy organizations. It operates in Israel and the US. Gamida is headquartered in Kiryat Gat, Israel.
For a complete picture of CordIn’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
